<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lu YP</submitter><funding>Zhao Yi-Cheng Medical Science Foundation</funding><pagination>683-696</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8443994</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>39(4)</volume><pubmed_abstract>&lt;h4>Purpose&lt;/h4>We conducted a systematic review and meta-analysis to quantify the association between phosphodiesterase type 5 inhibitors (PDE5Is) use and skin cancers and we also examined whether down-expression of the PDE5A gene was related to worse prognosis for malignant melanoma (MM) patients.&lt;h4>Materials and methods&lt;/h4>The PubMed, Cochrane Library, Web of Science, EMBASE, and ClinicalTrails.gov databases were searched. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to evaluate the association between PDE5Is use and risk of skin cancers. Cumulative meta-analysis and trial sequential analysis (TSA) were also conducted. Survival outcomes were analyzed online.&lt;h4>Results&lt;/h4>After pooling all 8 eligible studies comprising 7,479,852 subjects, we found that PDE5Is </pubmed_abstract><journal>The world journal of men's health</journal><pubmed_title>Phosphodiesterase Type 5 Inhibitors and Risk of Skin Cancers in Men: A Meta-Analysis and Trial Sequential Analysis Involving 7,479,852 Subjects.</pubmed_title><pmcid>PMC8443994</pmcid><funding_grant_id>ZYYFY2018031</funding_grant_id><pubmed_authors>Liu X</pubmed_authors><pubmed_authors>Liu K</pubmed_authors><pubmed_authors>Yang Y</pubmed_authors><pubmed_authors>Liang Z</pubmed_authors><pubmed_authors>Lu YP</pubmed_authors><pubmed_authors>Wang X</pubmed_authors><pubmed_authors>Kang J</pubmed_authors><pubmed_authors>Fan S</pubmed_authors><pubmed_authors>Zhou K</pubmed_authors><pubmed_authors>Song Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Phosphodiesterase Type 5 Inhibitors and Risk of Skin Cancers in Men: A Meta-Analysis and Trial Sequential Analysis Involving 7,479,852 Subjects.</name><description>&lt;h4>Purpose&lt;/h4>We conducted a systematic review and meta-analysis to quantify the association between phosphodiesterase type 5 inhibitors (PDE5Is) use and skin cancers and we also examined whether down-expression of the PDE5A gene was related to worse prognosis for malignant melanoma (MM) patients.&lt;h4>Materials and methods&lt;/h4>The PubMed, Cochrane Library, Web of Science, EMBASE, and ClinicalTrails.gov databases were searched. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to evaluate the association between PDE5Is use and risk of skin cancers. Cumulative meta-analysis and trial sequential analysis (TSA) were also conducted. Survival outcomes were analyzed online.&lt;h4>Results&lt;/h4>After pooling all 8 eligible studies comprising 7,479,852 subjects, we found that PDE5Is </description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Oct</publication><modification>2025-04-04T19:44:41.261Z</modification><creation>2022-02-11T11:31:10.168Z</creation></dates><accession>S-EPMC8443994</accession><cross_references><pubmed>33151043</pubmed><doi>10.5534/wjmh.200082</doi></cross_references></HashMap>